US 11,806,321 B2
Non-linear dosing of mirdametinib
Uchenna H Iloeje, Stamford, CT (US); Abraham J Langseth, Stamford, CT (US); and Todd Shearer, Stamford, CT (US)
Assigned to SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US)
Filed by SpringWorks Therapeutics Inc., Stamford, CT (US)
Filed on Mar. 16, 2023, as Appl. No. 18/185,045.
Claims priority of provisional application 63/321,036, filed on Mar. 17, 2022.
Claims priority of provisional application 63/321,046, filed on Mar. 17, 2022.
Prior Publication US 2023/0293462 A1, Sep. 21, 2023
Int. Cl. A61K 31/166 (2006.01); A61P 25/00 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/166 (2013.01) [A61K 9/0053 (2013.01); A61P 25/00 (2018.01); A61P 35/00 (2018.01)] 24 Claims
 
1. A method of administering mirdametinib to a human patient in need thereof comprising orally administering mirdametinib to the patient, wherein the patient suffers from a tumor or cancer, and wherein
(a) for a patient having a body surface area no more than 0.69 m2, the patient is initially administered 1 mg mirdametinib twice daily,
(b) for a patient having a body surface area of 0.7 to 1.04 m2, the patient is initially administered 2 mg mirdametinib twice daily,
(c) for a patient having a body surface area of 1.05 to 1.49 m2, the patient is initially administered 3 mg mirdametinib twice daily, and
(d) for a patient having a body surface area of at least 1.5 m2, the patient is initially administered 4 mg mirdametinib twice daily.